Long-Term Follow-Up of a High Risk Cohort After Stent Implantation in Saphenous Vein Grafts  by Frimerman, Aaron et al.
Long-Term Follow-Up of a High Risk Cohort After Stent Implantation
in Saphenous Vein Grafts
AARON FRIMERMAN, MD, ELDAD RECHAVIA, MD, NEAL EIGLER, MD, FACC,
MONICA R. PAYTON, BS, PAC, RAJ MAKKAR, MD, FRANK LITVACK, MD, FACC
Los Angeles, California
Objectives. We sought to provide short- and long-term clinical
outcomes of a high risk cohort treated with stents in saphenous
vein grafts (SVGs).
Background. Data on the long-term outcome of SVG stenting in
high risk patients are limited.
Methods. Johnson & Johnson stents were implanted in the
SVGs of 186 patients (302 stents, 244 lesions). Ninety percent of
patients presented with myocardial infarction (MI) or unstable
angina (mean 6SD ejection fraction [EF] 44 6 11%, patient age
71 6 9 years, graft age 9.4 6 5 years). Using a risk score
classification, 155 patients (83%) were defined as high risk for
repeat surgical repair or angioplasty.
Results. The procedural success rate was 97.3%, with 2.7%
major complications (death, Q wave MI, coronary artery bypass
graft surgery [CABG]). Clinical follow-up was obtained in 177
patients (mean 19.1 6 13.5 months, range 7 to 59). Event rates
were 10% for death; 9% for MI; 11% for repeat CABG; and 15% for
repeat angioplasty (total events 45%). Kaplan-Meier estimated
survival and event-free survival at 4 years were 0.79 6 0.06 and
0.29 6 0.07, respectively. Predictors of death were congestive heart
failure (p < 0.01) and EF <44% (p < 0.05). Predictors of
combined events of death, MI and CABG were low EF (p < 0.01)
and high SVG age (>10 years, p < 0.01). There were 66 revascu-
larization procedures (35% of patients), 24% of which were in
nontarget lesions. Fifty-three percent of the cardiac events oc-
curred during the first year of follow-up. Of the 160 survivors, 36%
were free of angina, 49% were in Canadian Cardiovascular Society
functional class I or II, and 15% were in class III or IV. Sixty-nine
percent of patients were in class I or II according to the Specific
Activity Scale, and 31% of patients were in class III or IV.
Conclusions. Balloon-expandable stent implantation in the
SVGs of high risk patients is associated with a low early compli-
cation rate. Expected survival rates are good, as are the anginal
and functional classifications, but there is a high rate of recurrent
events and need for repeat revascularization. Vein graft stenting is
an acceptable palliative option in many high risk patients.
(J Am Coll Cardiol 1997;30:1277–83)
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Patients undergoing coronary artery bypass graft surgery
(CABG) often require repeat revascularization over time.
Revascularization rates of 19% at 10 years and 30% at 12 years
have been reported (1). These events are usually the result of
saphenous vein graft (SVG) failure, which has been reported
to be as high as 75% at 10 years (1–3). As several million
people worldwide have undergone CABG over the past two
decades, a large cohort of patients with previous CABG now
exists, establishing a significant public health and economic
problem.
Treatment of patients previously operated on by either
transcatheter or surgical revascularization is frequently prob-
lematic. Repeat CABG has a periprocedural death and myo-
cardial infarction (MI) rate of 2% to 5% and 2% to 8%,
respectively. Five-year event-free and angina-free survival
rates have been reported as 64% and 50%, respectively (2,4,5).
Some patients are not well suited for reoperation because of
small or diffusely diseased target vessels, poor left ventricular
function or a lack of available conduit or comorbid conditions.
Percutaneous transluminal coronary angioplasty (PTCA) may
be performed with relatively high angiographic success rates,
although intraprocedural complications including distal embo-
lization, no-reflow and MI are substantially higher than those
with native coronary angioplasty. The 6-month restenosis rates
have been unacceptably high—.50% in several studies (6,7).
Deployment of stents in SVG lesions has become the
standard of care in many centers in the United States and
abroad. Several studies have reported high procedural success
rates and acceptable major complication rates. Although no
randomized trial data are yet available, the 6-month clinical
outcomes and angiographic restenosis rates have been viewed
as lower than those expected with balloon angioplasty alone
(8–12). Data on the widely used balloon expandable Johnson
& Johnson stent are limited by the exclusion of some high risk
conditions including MI, diffuse graft disease, thrombus or
slow flow and ostial or distal location. Follow-up data are also
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limited in duration (8,10,12). However, the Johnson & John-
son stent is commonly used for the treatment of these exact
clinical problems, although little is known about the long-term
outcomes in such patients.
We present our experience with balloon expandable stents
in the vein grafts of consecutive patients with a variety of high
risk clinical and angiographic characteristics. We provide
long-term clinical follow-up results as well as comprehensive
statistical analysis with respect to the correlates of adverse
long-term events.
Methods
Patients. Between April 1991 and October 1995, 186 pa-
tients had balloon expandable stents placed in vein grafts at
Cedars-Sinai Medical Center. Patients had clinical evidence of
myocardial ischemia related to the treated vessel, with the
stenotic lesion .50% in diameter in any location within the
vein graft. Patients with contraindications to antiplatelet or
anticoagulation therapy or vein graft diameter ,3 mm were
excluded (clinical characteristics of patient cohort are summa-
rized in Table 1). Patient therapy was selected at the discretion
of the physician after written informed consent by the patient.
The investigational vein graft stenting protocol was approved
by the Institutional Review Board. The patients who received
stents do not represent all patients with SVG disease treated
during the study period.
All the patients had multivessel coronary artery disease or
left main coronary stenosis. One hundred thirteen patients
(61%) were .70 years and 32 (17%) were .80 years of age.
One hundred twenty two patients (66%) had an history of MI,
including 38 (20%) within 30 days of angioplasty. One hundred
fifty nine patients (85%) presented with rest angina (Braun-
wald class II or III [13]) and 167 (90%) presented with an
unstable coronary syndrome (either unstable angina [Braun-
wald classes I to III] or acute MI).
Stent implantation. All the lesions were predilated by
conventional PTCA, and stents were deployed by balloon
inflation. Ninety percent of stents were further expanded with
large or high pressure balloons at the operator’s discretion. In
30 patients (16%), at the operator’s discretion, the final stent
apposition in the artery was evaluated by intravascular ultra-
sound imaging. Mean maximal balloon size and pressure were
3.8 6 0.6 mm and 13.4 6 4 atm, respectively. The balloon/
artery ratio was 1.18 6 0.23:1.
Medical regimen. All patients were pretreated with aspirin
(325 mg/day); 75 patients (40%) received premedication with
dipyridamole (75 mg three times a day). Heparin was given
during the procedure and titrated to maintain an activated
clotting time .300 s. All patients continued to receive aspirin
indefinitely. Sixty six percent of the patients received warfarin
after the procedure, as previously recommended (14). The
more recently treated patients (18%) received ticlopidine
(250 mg twice a day for 2 to 4 weeks) without additional
warfarin, and 16% of patients received both warfarin and
ticlopidine.
Follow-up. Within 18 h of the procedure, serum creatine
kinase levels were measured and a 12-lead electrocardiogram
(ECG) was obtained. Infarction was diagnosed if the total CK
level was .200 IU with positive (.5%) MB isoform. Long-
term clinical follow-up was obtained using two standard ques-
tionnaires. One was sent to the patient’s referring physician
and included detailed medical information of clinical events
(death, MI or any revascularization procedure), symptom
classification (Canadian Cardiovascular Society [CCS] classifi-
cation) and functional/activity class (Specific Activity Scale
[SAS]) (15). Another questionnaire was sent directly to the
patients and included the previously mentioned events as well
as self-assessment of symptom and activity level, by CCS and
SAS classifications. If forms were not returned, patients were
interviewed by telephone. In case of discordance between the
patient’s and the physician’s functional assessments, the pa-
tient’s assessment was considered to be more reliable.
Follow-up angiography was performed for clinical indications
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
CCS 5 Canadian Cardiovascular Society
ECG 5 electrocardiogram, electrocardiographic
EF 5 ejection fraction
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
SAS 5 Specific Activity Scale
SVG 5 saphenous vein graft
TIMI 5 Thrombolysis in Myocardial Infarction
Table 1. Clinical Characteristics of 186 Patients
Age (yr) 71 6 9
Male gender 156 (84%)
Diabetes mellitus 46 (25%)
Hypertension 98 (53%)
Cholesterol .200 mg/dl 98 (53%)
History of smoking at any time 84 (45%)
History of CHF 46 (25%)
Unstable angina 159 (85%)
Recent MI (,1 mo) 38 (20%)
Previous MI (.1 mo) 84 (45%)
Previous multiple CABG 56 (30%)
Previous PTCA at intervention site 31 (17%)
LVEF (%) 44 6 11*
High surgical risk 97 (52%)
Procedural risk
Low 5 (3%)
Moderate 91 (49%)
High 75 (40%)
Very high 15 (8%)
*Data are available for 88% of patients. Data presented are mean value 6
SD or number (%) of patients. CABG 5 coronary artery bypass graft surgery;
CHF 5 congestive heart failure; LVEF 5 left ventricular ejection fraction; MI 5
myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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only. Restenosis was defined as .50% diameter narrowing at
the stent site. Available medical records and angiographic data
were analyzed to validate the information and to determine
target vessel and target site failure.
Angiographic analysis. The cineangiograms of all the pa-
tients were reviewed by a single experienced observer (A.F.).
Qualitative analysis of the angiographic data included assess-
ment of the Thrombolysis In Myocardial Infarction trial
(TIMI) flow grade, lesion type by morphology (modified
American Heart Association/American College of Cardiology
classes A, B1, B2 and C as defined by Ellis et al. [16]) and the
presence of thrombus. Quantitative angiographic measure-
ments included 1) reference vessel diameter; 2) minimal lumen
diameter and percent stenosis before and at the end of the
procedure; 3) acute gain; 4) lesion length; and 5) recipient
artery diameter. End-diastolic frames with the most severe
narrowing in the projection that best demonstrated the target
lesion were selected throughout the study. The measurements
were performed using an automated computer-assisted edge-
detection algorithm with magnification calibrated from the
guiding catheter diameter (Imagecomm Systems), as previ-
ously reported (17).
Statistical analysis. Data are expressed as mean value 6
SD. Survival rates were estimated using the Kaplan-Meier
method for freedom from: 1) death; 2) death and Q wave MI;
3) death, MI and CABG; and 4) death, MI, CABG and
catheter-based revascularization. Predictors of time to event
were determined by the Cox proportional hazards model. Fifty
clinical, anatomic and technical variables were analyzed to
determine their importance as predictors of time to event.
These variables included age, gender, diabetes mellitus, hyper-
tension, hyperlipidemia, smoking, family history, previous MI,
recent MI, unstable angina, ejection fraction (EF), heart
failure, previous multiple CABGs, vein graft age, restenosis
lesion, bailout procedure, suboptimal result, stent number,
balloon size and maximal pressure, stented graft to different
coronary arteries (left anterior descending, left circumflex,
right artery), stented site in graft (proximal, mid, distal),
warfarin therapy, ticlopidine therapy, lesion type (A, B1,
B2, C), thrombus in graft, lesion length, multiple lesion
treated, stent overlap, preprocedure and postprocedure TIMI
flow grade (0–1,2,3), reference vein graft diameter, recipient
artery diameter, preprocedure and postprocedure minimal
lumen diameters and percent stenosis, acute lumen gain and
early complications.
The Mann-Whitney U test was used to compare nonpara-
metric variables. A p value ,0.05 was considered significant.
All analyses were performed using BMDP Statistical Software
(University of California Press, Berkeley).
Definitions. Patients were scored for high surgical risk or
high procedural risk according to previously published criteria:
High surgical risk. These patients had one or more of the
following variables: severe or multiple comorbid condition
(e.g., renal insufficiency, pulmonary disease); poor left ventric-
ular function (EF ,40%); more than one previous CABG
(18).
High procedural risk. Patients were graded by predictors of
major angioplasty complications: unstable angina, recent MI,
age .70 years and type C lesion. Risk scores were classified
into four classes: low (none of the previously mentioned risk
factors present), moderate (one or two risk factors present),
high (three risk factors) and very high (more than three risk
factors) (19).
Procedural success. These patients had successful stent
deployment with ,50% residual stenosis and without major
in-hospital complications, including death, Q wave MI, surgical
or catheter-based revascularization and subacute thrombosis.
Minor complications. This group included postprocedure
thrombus or embolus; Nonocclusive coronary dissection with
good flow; stent loss or stent migration without chest pain or
ECG changes; noncoronary dissection, fistula, pseudoaneu-
rysm and surgical repair; and significant bleeding or hema-
toma, stroke, fever and repeat angiogram within 48 h after
stent deployment without significant narrowing in the stent
site.
Results
Demographics. The mean target vein graft age was 9.4 6
4.5 years, and 89% of the grafts were $4 years old. Internal
mammary artery grafts were used in 80 patients (43%). Sixty-
nine patients (37%) had a left ventricular EF ,45%, and 46
patients (25%) had history of congestive heart failure (New
York Heart Association class III or IV). Fifty-six patients
(30%) had previous repeat CABG; 14 (7.5%) had severe or
multiple comorbid conditions (e.g., renal insufficiency, pulmo-
nary disease); and 97 (52%) were defined as high surgical risk
and 90 (48%) as high or very high procedural risk. One
hundred fifty-five patients (83%) were defined as either high
surgical or procedural risk. Sixty-four patients (34%) under-
went catheter-based angioplasty before the index stenting (72
procedures—72% balloon angioplasty, 18% stent placement,
8% laser, 1% directional atherectomy), and 43% of these
procedures were performed at the index stent site. Of the 244
total lesions, 17% were restenotic.
Immediate results and angiographic findings. Table 2
provides the location of the stents and qualitative angiographic
variables. Of 302 stents placed in 244 lesions, 292 were
Johnson & Johnson 15-mm long, articulated coronary stents
and 10 were Johnson & Johnson 10-mm long biliary stents. In
48 patients (26%), multiple lesions were treated in a single
graft, and in 8 patients, stents were placed in two separate vein
grafts in the same procedure. Of the 186 patients, 109 (59%)
received a single stent and 77 (41%) received multiple stents (2
stents in 47 patients, 3 stents in 22 patients, 4 stents in 7
patients and 5 stents in 1 patient). Sixty-five percent of the
treated lesions were type B2 (40%) or C (25%). The quanti-
tative angiographic data of these patients are summarized in
Table 3.
Complications. Procedural success was achieved in 181
patients (97.3%). In five patients (2.7%), the procedure was
unsuccessful because of major complications (Table 4). Two
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deaths occurred after subacute thrombosis. Both patients had
type C lesions that were treated by multiple and overlapping
stents deployed at maximal balloon pressure of 10 to 12 atm,
and they were treated with warfarin but not ticlopidine. Two
patients had Q wave MI. One patient with diffuse coronary and
vein graft disease had persistence rest angina after stent
placement. Repeat CABG was performed during his hospital
stay. There were no deaths or emergency CABGs during the
procedure. Non Q wave MI occurred in three patients (1.6%).
Late clinical follow-up. Of 181 eligible patients with suc-
cessful stent placement, clinical follow-up was obtained in 177
(98%) at an average of 19.1 6 13.5 months (range 7 to 59). The
incidence of hierarchic major clinical events (events in de-
scending order of severity: death followed by MI, CABG and
catheter-based revascularization) was 45% (Table 5). There
were three noncardiac deaths (one suicide, two complications
of noncardiac surgery). Of the 14 cardiac deaths, five were
sudden (one had an angiographically patent stent shortly
before death) and one was due to congestive heart failure. The
other deaths were caused by the coronary disease. Rates of
nonfatal MI, repeat CABG and catheter-based revasculariza-
tion were 9% (n 5 15), 11% (n 5 20) and 15% (n 5 27),
respectively.
Clinically guided repeat angiography was performed in 73
patients (41%) at 13.5 6 12 months. Target site restenosis was
found in 45 patients (62% of this selected group with a high
probability of clinical restenosis or 25% of the total follow-up
group). Of the 66 revascularization procedures (26 CABGs, 29
Table 2. Characteristics of 244 Lesions and Distribution of
302 Stents
Graft age (yr) 9.4 6 4.5
Stent distribution in SVG to
LAD 129 (43%)
LCx/OM 90 (30%)
RCA 83 (27%)
Treated lesion location in SVG
Ostial 57 (19%)
Proximal 66 (22%)
Body 133 (44%)
Distal 46 (15%)
Patients with multiple stents 77 (41%)
Lesion characteristics
Eccentric 37%
Calcified 2.4%
Diffuse 22.5%
Thrombus 11.5%
Lesion type
A 20%
B1 15%
B2 40%
C 25%
Data presented are mean value 6 SD; number (%) of stents, lesions or
patients; or percent of lesions. LAD 5 left anterior descending coronary artery;
LCx 5 left circumflex coronary artery; OM 5 obtuse marginal; RCA 5 right
coronary artery; SVG 5 saphenous vein graft.
Table 3. Angiographic Data Before and After Stenting
Reference vessel diameter (mm) 3.3 6 0.6
Lesion length (mm) 9.9 6 6.2
MLD (mm)
Before stenting 0.7 6 0.4
After stenting 2.9 6 0.5
% diameter stenosis
Before stenting 76 6 11
After stenting 10 6 12
Immediate gain (mm) 2.4 6 0.7
TIMI flow grade
Before stenting
0–1 12%
2 52%
3 36%
After stenting
0–1 0
2 10%
3 90%
Maximal balloon size (mm) 3.8 6 0.6
Maximal balloon pressure (atm) 13.4 6 4
Data presented are mean value 6 SD or percent of patients. MLD 5
minimal lumen diameter; TIMI 5 Thrombolysis in Myocardial Infarction.
Table 4. In-Hospital Outcome of 186 Patients
Major complication
Death 2 (1.1%)
Q wave MI 2 (1.1%)
CABG 1 (0.5%)
Total major complications 5 (2.7%)
Other complications
Non–Q wave MI 3 (1.6%)
Thrombosis (acute/subacute) 3 (1.6%)
Nonocclusive vein graft dissection 9 (4.8%)
Stroke 1 (0.5%)
Bleeding* 15 (8%)
Peripheral vascular complications† 9 (4.8%)
Total minor complications 42 (22.6%)
*Significant reduction in hemoglobin (.3 g/dl) or need for transfusion.
†Arterovenous fistula, pseudoaneurysm or surgical vascular repair. Data pre-
sented are number (%) of patients. Abbreviations as in Table 1.
Table 5. Clinical Follow-Up Outcomes of 177 Patients
Nonhierarchic* Hierarchic†
Major event
Death, total 17 (17%) 17 (10%)
Death, cardiovascular 14 (14%) 14 (8%)
Nonfatal MI 17 (17%) 15 (9%)
CABG 26 (26%) 20 (11%)
Catheter-based revascularization 40 (40%) 27 (15%)
Total major cardiac events 96 (97%) 76 (43%)
Total major events 99 (100%) 79 (45%)
Total revascularization procedures 66 (66%)
Nontarget lesion revascularization 16 (16%)
No major event 98 (55%)
*Number of events of each type (proportion using total of all events as
denominator). †Number of events in descending order of severity and the
percentage of patients with event. Abbreviations as in Table 1.
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balloon angioplasties and 11 stent placements), 16 (24%) were
not associated with the index stent location and were per-
formed as the result of disease progression elsewhere (10 in
nontarget vessel and 6 in nontarget site in same vessel).
Of the 160 survivors, 58 (36%) were free of angina, 78
(49%) were in CCS class I or II and 24 (15%) were in CCS
class III or IV. The SAS activity level was class I or II in 110
(69%) and class III or IV in 50 (31%) patients. There were no
significant differences in angina (p 5 0.28) or activity (p 5
0.33) classes between the event-free patients and the patients
with clinical events (after repeat revascularization in 93%)
(Table 6). There was 5% discordance between the patient’s
and the physician’s functional assessment.
Survival and event-free survival. The mean (6SD)
Kaplan-Meier estimated survival at 4 years was 0.79 6 0.06
(95% confidence interval [CI] 67% to 91%). Freedom from
cardiac death at 4 years was 0.82 6 0.06 (95% CI 70% to 94%).
Freedom from MI at 4 years was 0.71 6 0.06 (95% CI 59% to
83%), and event-free survival at 4 years (from MI, CABG and
catheter-based revascularization) was 0.29 6 0.08 (95% CI
14% to 46%) (Figure 1).
Using the Cox proportional hazards model, predictors of
death (total) were congestive heart failure (p , 0.01) and low
left ventricular EF (,44%) (p , 0.05). Predictors of the
combined events of death, MI and CABG were low left
ventricular EF (p , 0.01) and high vein graft age (.10 years)
(p , 0.01). There were no other significant clinical, anatomic
or technical predictors of adverse clinical events. Fifty-three
percent of the cardiac events occurred during the first year of
follow-up and 36% occurred during the first 6 months.
Ostial versus graft body stenting. Forty patients (22%)
had stents placed only at the graft’s ostium and 99 (53%) had
stents placed only in the body of the graft. Ostial and graft
body ages were 8.7 6 4.5 and 9.8 6 4 years, respectively (p 5
0.2). In the ostial group, there were no major early complica-
tions, but in the graft body group there were 4 (4%) major
complications (1 death, 2 Q wave MIs and 1 CABG; p 5 0.04).
The ostial group had a 55% long-term event rate, with 5%
nontarget site revascularization and 0.27 6 0.1 Kaplan-Meier
estimated event-free survival at 3 years. The graft body group
had a 42% long-term event rate (13% nontarget site revascu-
larization), with 0.35 6 0.08 Kaplan-Meier estimated event-
free survival at 3 years (p 5 0.06).
Table 6. Follow-Up Angina Pectoris and Activity Classes in
Surviving Patients
Event Free
(n 5 100)
Clinical Events
(n 5 60)*
Total Survivors
(n 5 160)
Angina pectoris†
No angina 39 (39%) 19 (32%) 58 (36%)
CCS class I 18 (18%) 23 (38%) 41 (26%)
CCS class II 31 (31%) 6 (10%) 37 (23%)
CCS class III 10 (10%) 10 (17%) 20 (12.5%)
CCS class IV 2 (2%) 2 (3%) 4 (2.5%)
CCS median class I I I
Activity class
SAS I 48 (48%) 16 (27%) 64 (40%)
SAS II 19 (19%) 27 (45%) 46 (29%)
SAS III 27 (27%) 7 (12%) 34 (21%)
SAS IV 6 (6%) 10 (16%) 16 (10%)
SAS median class II II II
*Ninety-three percent of patients underwent a repeat revascularization
procedure. †Data presented are number (%) of patients, unless otherwise
indicated. CCS 5 Canadian Cardiovascular Society; SAS 5 Specific Activity
Scale (I 5 best; IV 5 worst).
Figure 1. Kaplan-Meier survival curves of
major cardiac events: death, MI, repeat
CABG and repeat catheter-based interven-
tion (INTV).
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Discussion
This study is different from previous reports of vein graft
stenting by virtue of the high risk nature of the patient cohort
and their length of clinical follow-up. Previous reports have
evaluated the results of Johnson & Johnson stents in SVGs.
The multicenter study by Wong et al. (8) included patients with
focal stenosis with relatively good flow in vein graft shafts. That
study specifically excluded patients with MI, ostial location,
distal or diffuse disease and thrombotic lesions. Similarly,
Fenton et al. (12) excluded patients with MI and those with
tortuous, thrombotic or diminished flow. Piana et al. (10)
excluded patients with diffuse disease or thrombotic vein graft
lesions. Several previous studies with balloon angioplasty have
established that these clinical and angiographic characteristics
are associated with higher early procedural risks and less
favorable intermediate- and long-term outcomes (19–22). Our
cohort had a relatively advanced age (mean 71 6 9 years) and
reduced left ventricular function (left ventricular EF 44 6
11%), as well as complex lesion morphology (65% had type B2
and C lesions) and a high frequency of presentation with acute
coronary syndromes (90%). Eighty-three percent of patients
were defined as high risk for either surgical repair or angio-
plasty by well established risk score classifications (18,19). The
length of clinical follow-up in this cohort allows for statistical
estimation of 4-year outcomes.
Immediate results. This study corroborates previous re-
ports that stent placement may be undertaken with an expec-
tation of high procedural success and low early complication
rates, even in patients with complications. The procedural
success rate in our study was 97.3%, and the major complica-
tion rate was 2.7%. These data are in line with those of
previous reports of balloon or self-expanding stents
(8,11,14,17,23). The 1.1% in-hospital mortality rate in this
study is lower than that previously reported for second bypass
surgery, where mortality rates vary from 2% to 5% (4). Three
patients (1.6%) in the cohort had subacute stent thrombosis
within the first 7 days of the procedure. Each of these patients
had a high grade lesion and was treated with more than one
stent. Each of them received anticoagulant therapy with war-
farin but no ticlopidine. The lack of major early complications
in the SVG ostium-only stent group compared with the 4%
complication rate in the SVG body-only stent group may be
explained by the relative paucity of friable material in the
ostium. This cohort had a high proportion of patients with
ostium-only stenting (22%). This may in part explain the low
incidence of distal embolization. We report a 13% incidence of
peripheral vascular or bleeding complications. These compli-
cations are likely to be associated with the frequent use of
warfarin and may well be mitigated by the current practice of
withholding that drug and using ticlopidine in most patients
(24).
Long-term results. These data provide interesting insight
into long-term outcomes of patients after they have had vein
graft stenting. The Kaplan-Meier estimate of 4-year survival of
0.79 6 0.06 is consistent with that of previous reports for
PTCA and CABG. Repeat CABG has been reported to
provide 70% to 90% survival, balloon angioplasty a 78%
survival rate at 4 years and the self-expanding Walstent an
estimated 83% survival rate at 5 years (4,23,25–27). Fifty
clinical, angiographic and technical variables were analyzed to
determine predictors of time to death. Of these, only conges-
tive heart failure and low left ventricular EF predicted early
death. Vein graft age .10 years was found to be a predictor of
combined events (death, MI or CABG), as has been reported
in relation to CABG reoperation (1–3). Notwithstanding the
relatively good survival data, recurrent events were disturb-
ingly frequent. The Kaplan-Meier estimate of 4-year survival
was 0.79 6 0.06, but the 4-year event-free survival was only
0.29 6 0.07. Of the total 66 repeat surgical or transcatheter
revascularization procedures (approximately two-thirds were
transcatheter), 16 (24%) were procedures performed on or
associated with lesions not related to the previously stented
sites. This corroborates previously reported data (10) that
progression of disease is an important contributor to morbidity
in these patients. Despite the more favorable early outcome in
the ostial-only group versus the body-only group, the long-term
estimated event-free survival is worse in the ostial group
(0.27 6 0.1 vs. 0.35 6 0.08 at 3 years, p 5 0.06). There was no
significant difference in graft age between the two groups
(ostial 8.7 6 4.5 vs. body 9.8 6 4 years, p 5 0.2), which could
account for these differences. These data reflect the problem of
maintaining long-term patency of an aorto-ostial lesion treated
by either PTCA or a new device. More than one-half of the
clinical events occurred within 12 months, indicating a need for
close vigilance in these patients during the first year after the
procedure. The majority of late interventions were related to
disease progression outside the target site. Seventy percent of
all nontarget site revascularization procedures were performed
2 years or later after the index stenting. The mean time to
revascularization in this group was 23 6 12 months.
The results with respect to follow-up angina pectoris and
activity classes in surviving patients are relatively favorable. Of
the 160 survivors, 58 (36%) had no angina and only 24 (15%)
were in CCS angina class III or IV. Sixty-nine percent of
patients reported an SAS class of I or II, whereas only 31%
reported class II or III. There were no significant differences in
either CCS (angina) or SAS class in patients who proceeded
through their follow-up event-free compared with those who
had clinical events, although 93% of the cohort with events
underwent repeat revascularization.
Study limitations. These data are based on patients treated
at a single center and evaluated retrospectively. The center is
a large tertiary care teaching hospital and as such may not be
free of selection bias. Because the study was not randomized,
conclusions must be based on historic comparisons and con-
temporary clinical experience. Routine angiographic follow-up
was not part of our clinical practice, so insufficient data are
available to provide conclusions about the frequency and
nature of in-stent restenosis.
Conclusions. The management of patients who have had a
previous operation and who present with vein graft disease is
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complex and must be individualized. The present study pro-
vides several messages for clinicians. First, even in a high risk
patient cohort, stent implantation may be performed safely in
most patients. Second, such patients undergoing vein graft
stenting have an excellent prognosis for survival considering
the number of older patients and the frequency of comorbid
conditions. Third, vein graft stenting should be considered a
palliative procedure that provides a good expectation of relief
from disabling angina as well as a good functional activity level,
but with a disturbingly high frequency of repeat revasculariza-
tion procedures. Despite the obvious limitations of vein graft
stenting, for many patients it may represent the best available
therapeutic option. Other patients, especially those in rela-
tively good physical condition or in whom an internal mam-
mary graft is possible, may be best served by repeat CABG.
Finally, there is a major need for improved therapies. The
possibilities include but are not limited to complete arterial
revascularization during the first bypass operation; aggressive
attention to modification of risk factors known to be associated
with progression of vein graft disease; effective therapies for
the prevention of in-stent restenosis (e.g., drugs, brachythera-
py), and the availability of new synthetic or bioprosthetic
bypass conduits. Until such time that new therapies become
available, the judgment of the clinician and patient, based on
an understanding of contemporary outcomes, will be relied on.
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